[HTML][HTML] Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney, J Buyon… - Arthritis research & …, 2015 - Springer
Introduction Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies …
both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies …
Treatment of systemic lupus erythematosus patients with the BAFF antagonist" peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase …
W Stohl, JT Merrill, RJ Looney… - Arthritis research …, 2015 - pubmed.ncbi.nlm.nih.gov
Introduction Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies …
both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies …
Treatment of systemic lupus erythematosus patients with the BAFF antagonist" peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase …
W Stohl, JT Merrill, RJ Looney, J Buyon… - Arthritis Research & …, 2015 - go.gale.com
Introduction Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies …
both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies …
[HTML][HTML] Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney, J Buyon… - Arthritis Research & …, 2015 - ncbi.nlm.nih.gov
Methods SLE subjects with mild disease that was stable/inactive at baseline received either
a single dose of blisibimod (0.1, 0.3, 1, or 3 mg/kg subcutaneous [SC] or 1, 3, or 6 mg/kg …
a single dose of blisibimod (0.1, 0.3, 1, or 3 mg/kg subcutaneous [SC] or 1, 3, or 6 mg/kg …
[引用][C] Treatment of systemic lupus erythematosus patients with the BAFF antagonist" peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney, J Buyon… - Arthritis Research & …, 2015 - search.proquest.com
Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
[PDF][PDF] Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney, J Buyon, DJ Wallace… - 2015 - cyberleninka.org
Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
[HTML][HTML] Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney… - Arthritis …, 2015 - arthritis-research.biomedcentral.com
Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to both cell
membrane-expressed and soluble BAFF. The goal of these first-in-human studies was to …
membrane-expressed and soluble BAFF. The goal of these first-in-human studies was to …
[PDF][PDF] Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney, J Buyon, DJ Wallace… - 2015 - researchgate.net
Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
[PDF][PDF] Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind …
W Stohl, JT Merrill, RJ Looney, J Buyon, DJ Wallace… - 2015 - Citeseer
Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
both cell membraneexpressed and soluble BAFF. The goal of these first-in-human studies …
Treatment of systemic lupus erythematosus patients with the BAFF antagonist" peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase …
W Stohl, JT Merrill, RJ Looney, J Buyon… - Arthritis Research & …, 2015 - europepmc.org
Methods SLE subjects with mild disease that was stable/inactive at baseline received either
a single dose of blisibimod (0.1, 0.3, 1, or 3 mg/kg subcutaneous [SC] or 1, 3, or 6 mg/kg …
a single dose of blisibimod (0.1, 0.3, 1, or 3 mg/kg subcutaneous [SC] or 1, 3, or 6 mg/kg …